Parkinson’s Disease Plasma
Parkinson's Disease Plasma - Cryopreserved human plasma from IRB-consented donors with clinically confirmed Parkinson's disease. Suitable for alpha-synuclein and neurofilament light chain assay work, neuronal extracellular vesicles, proteomics, lipidomics, and metabolomics. GBA1 and LRRK2 carrier stratification available. Acellular matrix.
| Lot # | Condition | Volume | Race/Ethnicity | Age | Gender | Country of Collection | Medications | Vials | Price | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| 78385 | Parkinson's Disease | 1.0 ML | 74 | Female | Ukraine |
Acetylsalicylic acid, Bisoprolol, Carbidopa/levodopa
|
1 | $495.00 | ||
| 78386 | Parkinson's Disease | 1.0 ML | 74 | Female | Ukraine |
Acetylsalicylic acid, Bisoprolol, Carbidopa/levodopa
|
1 | $495.00 | ||
| 78387 | Parkinson's Disease | 1.0 ML | 74 | Female | Ukraine |
Acetylsalicylic acid, Bisoprolol, Carbidopa/levodopa
|
1 | $495.00 | ||
| 78433 | Parkinson's Disease | 1.0 ML | 72 | Male | Ukraine |
Acetylsalicylic acid, Bisoprolol, Carbidopa/levodopa
|
1 | $495.00 | ||
| 78434 | Parkinson's Disease | 1.0 ML | 72 | Male | Ukraine |
Acetylsalicylic acid, Bisoprolol, Carbidopa/levodopa
|
1 | $495.00 | ||
| 78388 | Parkinson's Disease | 1.0 ML | 74 | Female | Ukraine |
Acetylsalicylic acid, Bisoprolol, Carbidopa/levodopa
|
1 | $495.00 | ||
| 78389 | Parkinson's Disease | 1.0 ML | 74 | Female | Ukraine |
Acetylsalicylic acid, Bisoprolol, Carbidopa/levodopa
|
1 | $495.00 | ||
| 78435 | Parkinson's Disease | 1.0 ML | 72 | Male | Ukraine |
Acetylsalicylic acid, Bisoprolol, Carbidopa/levodopa
|
1 | $495.00 | ||
| 78390 | Parkinson's Disease | 1.0 ML | 74 | Female | Ukraine |
Acetylsalicylic acid, Bisoprolol, Carbidopa/levodopa
|
1 | $495.00 | ||
| 78436 | Parkinson's Disease | 1.0 ML | 72 | Male | Ukraine |
Acetylsalicylic acid, Bisoprolol, Carbidopa/levodopa
|
1 | $495.00 |
Parkinson’s Disease Plasma for Neurodegeneration Biomarker Research
Parkinson’s Disease Plasma is collected from IRB-consented donors clinically diagnosed with Parkinson’s disease and processed within one day of collection to preserve labile analytes such as neuronal proteins, cytokines, lipids, and metabolites. Cryopreserved and available in custom aliquots, with standardized pre-analytical handling. Research Use Only (RUO).
Neurodegeneration and Why Plasma
- Parkinson’s disease is a progressive neurodegenerative disorder defined by loss of dopaminergic neurons in the substantia nigra and by Lewy pathology composed of aggregated alpha-synuclein.
- Alpha-synuclein aggregation is the central molecular event and the target of multiple therapeutic programs, so quantifying and characterizing circulating alpha-synuclein species is an active area of blood-based biomarker research.
- Blood alpha-synuclein measurement requires careful pre-analytical control because erythrocytes contain abundant alpha-synuclein and hemolysis confounds results. Our standardized processing is designed to support this kind of work.
- Neurofilament light chain is an established plasma marker of neuroaxonal injury and is widely used in parkinsonian research, including in studies distinguishing Parkinson’s disease from atypical parkinsonian syndromes.
- Genetic risk is dominated by variants in GBA1 and LRRK2; these define enrichment cohorts for targeted therapeutics and are accompanied by measurable changes in relevant lipid and metabolic analytes.
- Plasma is acellular. This product is for soluble protein, extracellular vesicle, lipidomic, and metabolomic analysis, and does not support flow cytometry, immunophenotyping, or any other cell-based assay.
Donor Stratification Available
- Disease duration since diagnosis and Hoehn and Yahr stage where documented
- Motor phenotype: tremor-dominant versus postural instability and gait difficulty
- Presence of cognitive impairment or Parkinson’s disease dementia
- Genotype where documented: GBA1 or LRRK2 variant carriers
- Treatment status: levodopa, dopamine agonist, MAO-B inhibitor, deep brain stimulation, or treatment-naive
- Age at onset, including early-onset donors, plus sex and self-reported race/ethnicity
- Matched healthy controls available, age- and sex-matched on request
Product Features
- Research Use Only (RUO)
- Plasma collected from clinically confirmed Parkinson’s disease donors
- Processed within one day of collection
- Cryopreserved for long-term stability
- Standardized anticoagulant and processing workflow; custom aliquot volumes on request
- IRB-approved protocols and electronic informed consent
De-identified Donor Data
- Verified Parkinson’s disease diagnosis
- Demographic data: age, sex assigned at birth, race/ethnicity
- Donor-reported medications, allergies, and comorbidities
- Disease duration, motor phenotype, and cognitive status where available
- Additional Parkinson’s disease-specific metadata available on request
Applications
- Alpha-synuclein immunoassay and aggregation assay development
- Neurofilament light chain and neuroaxonal injury marker measurement
- Neuronally enriched extracellular vesicle isolation and cargo analysis
- Plasma proteomics for progression and prognostic biomarker discovery
- Lipidomics relevant to GBA1-directed therapeutic programs
- Untargeted metabolomics and oxidative stress analyte research
- Circulating inflammatory mediator profiling in neurodegeneration
- Disease-state matrix for diagnostic assay validation and differential diagnosis research
Other Parkinson’s Disease Specimen Types
- Parkinson’s Disease Serum
- Parkinson’s Disease Whole Blood
- Parkinson’s Disease PBMC
- Parkinson’s Disease Cerebrospinal Fluid
Compliance and Quality Assurance
- IRB-approved and HIPAA-compliant protocols
- Electronic informed consent with 21 CFR Part 11-compliant e-signatures
- Documentation support available for regulatory review
Ordering & Customization
Parkinson’s Disease Plasma is available in standard and custom volumes. For pricing, availability, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To browse all matrices and disease states, visit our human plasma page.
Protocols & Documentation
-
Download
Plasma Isolation
Protocol for plasma separation from anticoagulated whole blood, including processing, storage, and traceability requirements.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
Plasma
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – all our products are research use only (RUO).
1 Answer
You can find our full product catalog here.
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: Quality and Compliance
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom Plasma cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.